Innate Pharma Announces Conference Call and Webcast
Business Wire (Fri, 14-Aug 5:30 AM ET)
Market Chameleon (Mon, 10-Aug 6:32 AM ET)
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
PRNewswire (Mon, 10-Aug 2:33 AM ET)
Business Wire (Mon, 10-Aug 2:30 AM ET)
Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
Business Wire (Mon, 10-Aug 2:00 AM ET)
Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference
Business Wire (Thu, 23-Jul 1:00 AM ET)
Business Wire (Tue, 21-Jul 1:00 AM ET)
FDA Clears TELLOMAK 3 Phase 3 Trial for Lacutamab—IPHA Advances in Rare Cancer Research
Market Chameleon (Mon, 10-Nov 6:18 AM ET)
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Innate Pharma S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol IPHA.
As of September 1, 2026, IPHA stock price climbed to $2.19 with 299 million shares trading.
IPHA has a beta of 1.26, meaning it tends to be more sensitive to market movements. IPHA has a correlation of 0.05 to the broad based SPY ETF.
IPHA has a market cap of $244.62 million. This is considered a Small Cap stock.
Last quarter Innate Pharma S.A. - American Depositary Shares reported $10 million in Revenue and -$.64 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.01.
In the last 3 years, IPHA traded as high as $3.51 and as low as $1.17.
IPHA has underperformed the market in the last year with a price return of +1.4% while the SPY ETF gained +19.3%. However, in the short term, IPHA had mixed performance relative to the market. It has outperformed in the last 3 months, returning +19.7% vs +1.0% return in SPY. But in the last 2 weeks, IPHA shares have been beat by the market, returning -3.1% compared to an SPY return of -1.4%.
IPHA support price is $2.02 and resistance is $2.32 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IPHA shares will trade within this expected range on the day.
